相关实验视频

Updated: Jan 14, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

对肌缩侧面硬化症 (ALS) 的反意义寡核类疗法:一个总体评论

Edward Jeong¹, Dan Li²

¹College of Medicine, Choate Rosemary Hall, Farmington, USA.

|October 27, 2025

概括

反感性寡核酸 (ASO) 疗法在治疗肌缩侧面硬化症 (ALS) 方面表现有前途. 虽然托弗森针对SOD1突变,但开发用于零星ALS的有效ASO仍然是一个挑战.

科学领域:

神经退行性疾病神经退行性疾病
遗传学是一个遗传学.
药理学药理学是一个学科.

背景情况:

肌缩侧面硬化症 (ALS) 或卢·盖里格病是一种致命的神经退行性疾病.
目前对ALS的治疗方法有限,这凸显了对新型治疗方法的需求.
反感性寡核酸 (ASO) 疗法是向ALS遗传基础的有希望的途径.

研究的目的:

通过准特定的遗传突变,研究ASO疗法在治疗ALS中的有效性.
审查最近在ALS的ASO开发方面的进展和挑战.

主要方法:

进行了对研究的综合审查.
使用关键词"ALS"和"ASO"搜索了PubMed数据库.
10多年前发表的研究被排除在外,以确保相关性.

主要成果:

评估了针对各种基因突变的多个ASO候选者.
只有针对SOD1基因突变的托弗森获得了更广泛使用的批准.
许多ASO治疗未能达到疗效终点,导致中止.
较为普遍的零星ALS仍然难以以目前的ASO策略为目标.

结论:

ASO疗法是一个正在发展的领域,有可能用于ALS治疗,特别是对于特定的遗传形式,如SOD1突变ALS.
对于大多数ALS病例,特别是零星ALS病例,开发有效的ASO仍然存在重大挑战.
在ASO技术的持续研究和开发对于推进ALS治疗选择至关重要.

关键词:

作为一种治疗方法.这是一种反感的寡核酸疗法.反感的寡核化物.家庭性肌缩侧面硬化症 (FAML)神经退行性疾病是一种神经退行性疾病.

更多相关视频

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...